Globin Solutions, Inc. develops heme-based antidotal therapies to treat human poisonings by utilizing globin chemistry and protein engineering techniques. Their focus is on creating effective treatments that can rapidly neutralize toxins, addressing a critical need in emergency medical care.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for human poisonings often lack the speed and efficacy needed to neutralize toxins quickly, leading to increased morbidity and mortality. Existing antidotes may have limited availability, slow onset of action, or significant side effects, leaving a critical gap in emergency medical care.
Solution
Globin Solutions is developing heme-based antidotal therapies designed for rapid and effective neutralization of toxins in human poisonings. By leveraging globin chemistry and protein engineering techniques, the company aims to create novel treatments that can quickly bind to and inactivate a wide range of poisonous substances. These therapies are intended to address the limitations of current antidotes by offering improved efficacy, faster onset of action, and reduced side effects. The focus is on providing emergency medical professionals with innovative tools to combat poisonings and improve patient outcomes.
Target Audience
The primary target audience includes emergency medical professionals, hospitals, and poison control centers that require effective and readily available antidotal therapies for treating human poisonings.
Features
- Heme-based antidotes designed for rapid toxin neutralization.
- Protein engineering techniques to optimize toxin-binding affinity.
- Broad-spectrum activity against a range of poisonous substances.
- Improved efficacy and faster onset of action compared to existing antidotes.
- Reduced side effect profile for enhanced patient safety.